menstrual cramping; 2 missed periods; current period 9 days and counting; menstruation abnormal; this is a spontaneous report received from a contactable reporter(s) (consumer or other non hcp) from the regulatory agency (ra). regulatory number: gb-mhra-webcovid-202202171638564230-wwry2 (ra). other case identifier(s): gb-mhra-adr 26614065 (ra). a 33 year-old female patient (not pregnant) received bnt162b2 (comirnaty), administration date 19dec2021 (batch/lot number: unknown) as dose 3 (booster), single for covid-19 immunisation. the patient's relevant medical history and concomitant medications were not reported. patient has not had symptoms associated with covid-19. not had a covid-19 test. patient last menstrual period date: 21nov2021. vaccination history included: bnt162b2 (dose 1, single), for covid-19 immunisation; bnt162b2 (dose 2, single), for covid-19 immunisation. the following information was reported: dysmenorrhoea (medically significant), outcome "recovering", described as "menstrual cramping"; menstrual disorder (medically significant) with onset 21dec2021, outcome "not recovered", described as "menstruation abnormal"; menstruation irregular (medically significant), outcome "unknown", described as "2 missed periods"; heavy menstrual bleeding (medically significant), outcome "unknown", described as "current period 9 days and counting". ongoing and constant menstrual cramping, 2 missed periods, current period 9 days and counting. patient has not tested positive for covid-19 since having the vaccine. patient is not enrolled in clinical trial. the report does not relate to possible inflammation of the heart (myocarditis or pericarditis). the patient underwent the following laboratory tests and procedures: blood test: fine; ultrasound scan: fine. no follow-up attempts are possible; information about lot/batch number cannot be obtained. no further information is expected

test name: blood test; result unstructured data: test result:fine; test name: ultrasound; result unstructured data: test result:fine

na

na